AMAG Pharmaceuticals — Q3 2016 Earnings Presentation
35 slides from AMAG Pharmaceuticals's earnings presentation, Nov 3, 2016
Slide 1: AMAG Pharmaceuticals Q3-2016 Financial Results
AMAG Pharmaceuticals Q3-2016 Financial Results November 3, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, ex
Slide 3: Q3-2016 Earnings Call Agenda
Q3-2016 Earnings Call Agenda 3 Q3-2016 and Recent Highlights1 5 Q&A 2 Commercial Performance 4 Portfolio Expansion and 2016 Key Priorities 3 Financial Results and Guidance
Slide 4: Strong Revenue Growth
Strong Revenue Growth 4 GAAP Revenue ($M) 3Q-2015 3Q-2016 $96.2 $143.8 +50% YTD 2015 YTD 2016 $309.5 $380.5 +23% Makena CBRFeraheme Ex-US collaboration revenue1 1 Collaboration revenue related to the termination of AMAG’s ex-US ferumoxytol marketing agreement.
Slide 5: Q3-2016 Highlights and Recent Events
Q3-2016 Highlights and Recent Events 5 Drove significant top & bottom line growth in Q3-2016 – Achieved record sales of Makena; gained another 4 market share points – Increased enrollments at CBR vs. Q2-2016 – Maintained Feraheme market share – Realized strong operating income/adjusted EBITDA resu
Slide 6: Milestones: Next-Generation Development Programs
Milestones: Next-Generation Development Programs 6 Milestone 2016 2017 2018 Makena SQ Auto-Injector Program Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Definitive PK – dose 1st patient Pain study – dose 1st patient Topline data sNDA filed Expected approval Feraheme IDA Label Expansion Trial Q1 Q2 Q3 Q4 Q1 Q
Slide 7: Commercial Performance
amag Commercial Performance
Slide 8: Continued to Drive Makena Sales
Continued to Drive Makena Sales 8 Strong commercial execution ($M) M A T E R N A L H E A L T H : M A K E N A $65.2 $93.4 Q3-2015 Q3-2016 $184.3 $236.8 YTD 2015 YTD 2016 +43% +28%
Slide 9: Makena Market Opportunity and Share Gains
9 Makena 41% Off Guidance3 30% Compounded Hydroxyprogesterone Caproate 29% 1 Based on 140,000 patients, >16 injections/patient and net revenue of ~$425/injection. 2 Company estimates Makena market share based on distributor dispensing data and all other market share based on physician market researc
Slide 10: Makena Growth Drivers and Accomplishments
M A T E R N A L H E A L T H : M A K E N A 10 Continue share gains from compounders Increased Q3-2016 single-dose vial sales to 66% of total Makena sales, up from 30% in Q2-2016 1 Increase Makena @Home administration Increased average paid injections per patient to 14.2 weeks, up from 14.0 in Q2-
Slide 11: CBR Revenue: Return to Growth
11 $7.2 $28.0 Q3-2015 Q3-2016 $29.2 $29.9 Q3-2015 Q3-2016 +2.4% GAAP CBR Revenue Non-GAAP, Pro Forma CBR Revenue2 1 AMAG acquired CBR on August 17, 2015. 2 See slides 29-31 for reconciliations of GAAP to non-GAAP financial information. 3 Represents pro forma revenue. AMAG acquired CBR on August 17,
Slide 12: CBR Growth Drivers and Accomplishments
Growth Drivers Accomplishments 12 M A T E R N A L H E A L T H : C O R D B L O O D R E G I S T R Y Differentiate CBR’s offerings Enhanced messaging to capitalize on generational shift 1 Continue improvement in commercial execution and leverage field footprint Emphasized competitive advantages and
Slide 13: Feraheme: Differentiated Product, Expect Future Growth
H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E 13 $23.2 $22.3 Q3-2015 Q3-2016 Differentiated Product, Expect Future Growth ($M) $65.2 $70.8 YTD 2015 YTD 2016 +8.6% -4.2% In Q3-2016, IV iron market declined 4.2% versus Q2-2016 YTD 2016, IV iron market has grown 10.5%
Slide 14: Broad IDA Label Would Double Market Opportunity
Broad IDA Label Would Double Market Opportunity1 14 Feraheme ~26% Other IV irons ~74% IDA IV Iron Market (non-dialysis) Opportunity with Broad IDA indication1 ~$660M / year (non-dialysis)2 IDAIDA-CKD IDA-CKD IDA 4.5 million Americans diagnosed with IDA3 1.5 million in women’s health3 1 If regulatory
Slide 15: Feraheme Growth Drivers and Accomplishments
Growth Drivers Accomplishments H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E Growth in key segments Completed agreement with a large hospital GPO for expanded access to more than 100,000 grams of IV iron annually 1 Optimize net revenue per gram Continued sustainable & predictable broad
Slide 16: Financial Results
Financial Results
Slide 17: GAAP Total Revenue and Operating Income
GAAP Total Revenue and Operating Income (Loss) ($M) 17 GAAP Total Revenue 3Q-2015 3Q-2016 $96.2 $143.8 Makena CBRFeraheme GAAP Operating Income (Loss) ($1.4) $38.8 3Q-2015 3Q-2016 1 1 AMAG acquired CBR on August 17, 2015.
Slide 18: Q3-2016 Financial Summary
Q3-2016 Financial Summary 18 ($M, except per share data) Q3-2016 (GAAP) Adjustments Q3-2016 (Non-GAAP) Total revenues $143.8 $2.0 4 $145.8 Cost of revenue 30.7 (21.3) 6,7 9.4 Gross profit $113.1 $23.3 $136.4 Operating expenses 74.3 (14.1) 8,9 60.2 Operating income / Adjusted EBITDA $38.8 $37.4 $76.2
Slide 19: Non-GAAP Revenue Growth Translates into Strong Adjusted EBITDA
Non-GAAP Revenue Growth Translates into Strong Adjusted EBITDA 19 3Q-2015 3Q-2016 $103.5 $145.8 Non-GAAP Total Revenue1 Non-GAAP Adjusted EBITDA1 $52.8 $76.2 3Q-2015 3Q-2016 +44% +41% For the 3-months ended September 30 ($M) 1 See slides 29-31 for reconciliations of GAAP to non-GAAP financial inform
Slide 20: Strong Cash Flow Generation
Strong Cash Flow Generation 20 ($M) 9/30/16 12/31/15 Cash, cash equivalents and investments $614 $466 Principal debt outstanding Convertible senior notes (2.5%) $200 $200 Term loan facility (4.75%) 333 346 2023 senior notes (7.875%) 500 500 Total debt outstanding $1,033 $1,046 ($M) 9/30/16 12/31/15
Slide 21: Non-GAAP Revenue Growth Translates into Strong Adjusted EBITDA (YTD)
Non-GAAP Revenue Growth Translates into Strong Adjusted EBITDA 21 YTD 2015 YTD 2016 $276.9 $396.1 Non-GAAP Total Revenue1 Non-GAAP Adjusted EBITDA1 $152.1 $188.3 YTD 2015 YTD 2016 +24% +43% For the 9-months ended September 30 ($M) 1 See slides 29-31 for reconciliations of GAAP to non-GAAP financial
Slide 22: Updated 2016 Financial Guidance
Updated 2016 Financial Guidance Range 22 ($M) 2016 GAAP Guidance 2016 Non-GAAP Guidance Previous Updated Previous1 Updated1 Makena sales $310 - $340 $330 - $340 $310 - $340 $330 - $340 Feraheme/MuGard sales $95 - $105 $95 - $105 $95 - $105 $95 - $105 CBR revenue $98 - $108 $98 - $108 $115 - $1252 $1
Slide 23: Portfolio Expansion and 2016 Key Priorities
AMAG Pharmaceuticals Portfolio Expansion and 2016 Key Priorities November 3, 2016
Slide 24: Transforming AMAG through M&A and Licensing
Transforming AMAG through M&A and Licensing 24 Future Well-diversified portfolio of products Mix of commercial assets and development pipeline for long-term growth Enhanced internal capabilities that come with scaled organization Today Profitable company with strong growth Multiple therape
Slide 25: Portfolio Expansion
Portfolio Expansion Acquire Innovative Products with Long-Term Growth Potential 25 Strong financial profile, management team & corporate infrastructure Commercial & Digital Expertise Maternal Health Hematology / Oncology, Nephrology & Hospital Future product Makena® Feraheme® MuGard® New therapeutic
Slide 26: Executing on Key 2016 Milestones
Executing on Key 2016 Milestones 26 2016 Commercialize single-dose, preservative-free formulation Initiate definitive PK and comparative pain studies for subcutaneous auto-injector Initiate a head-to-head Phase 3 clinical trial in Q1-2016 evaluating the safety of Feraheme compared to Injectafe
Slide 27: Q&A
AMAG Pharmaceuticals Q&A Q3-2016 Financial Results November 3, 2016
Slide 28: Appendix
AMAG Pharmaceuticals Appendix Q3-2016 Financial Results November 3, 2016
Slide 29: Reconciliation of Non-GAAP Adjustments to Net Income
Reconciliation of Non-GAAP Adjustments to Net Income for the 3- and 9- Months Ended September 30, 2016 and 2015 (unaudited, amounts in thousands) 29 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 GAAP revenues $ 143,782 $ 96,152 $ 380,500 $ 309,541 Service reven
Slide 30: Footnotes: Reconciliation of Non-GAAP Adjustments
Footnotes: Reconciliation of Non-GAAP Adjustments to Net Income for the 3- and 9- Months Ended September 30, 2016 and 2015 30 4 Represents purchase accounting adjustments related to deferred revenue in connection with the CBR acquisition. 5 Represents adjustments to exclude certain non-cash revenue
Slide 31: Reconciliation of GAAP to Non-GAAP Net Income and Adjusted Net Income Per Share
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and Adjusted Net Income Per Share for the 3- and 9-Months Ended September 30, 2016 and 2015 (unaudited, amounts in thousands, except per share data) 31 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 GAAP Net I
Slide 32: Reconciliation of 2016 Financial Guidance
Reconciliation of 2016 Financial Guidance of Non-GAAP Adjusted EBITDA and Non-GAAP Net Income 32 2016 Financial Guidance ($M) Previous Updated GAAP net income $0 - $30 $3 - $23 Adjustments: Interest expense, net 73 73 Provision for income tax 20 22 Operating income $93 - $123 $98 - $118 Purchase acc
Slide 33: Share Count Reconciliation
Share Count Reconciliation 33 1 Employee equity incentive awards, convertible notes and warrants would be anti-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the convertible notes. 2 Reflects the Non-GAAP dilutiv
Slide 34: CBR Non-GAAP Revenue Adjustment
CBR Non-GAAP Revenue Adjustment 34 PURCHASE ACCOUNTING FUTURE IMPACT $3.1 $58.8 $0 $10 $20 $30 $40 $50 $60 $70 Closing Date GAAP Write-Off Amount Deferred revenue balance on August 17, 2015 $17.0 $5.5 $5.4 $5.3 $55.4 $0 $10 $20 $30 $40 $50 2016 2017 2018 2019 2020-2078 Non-GAAP Addback Addback to ca
Slide 35: AMAG Pharmaceuticals Q3-2016 Financial Results
AMAG Pharmaceuticals Q3-2016 Financial Results November 3, 2016